|46.26||-0.7400||-1.57%||Vol 1.82M||1Y Perf -25.48%|
|Jun 24th, 2022 16:00 DELAYED|
|- -||- -%|
|Target Price||70.38||Analyst Rating||Strong Buy 1.46|
|Potential %||52.14||Finscreener Ranking||★+ 42.41|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★ 40.60|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★+ 40.47|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||41.23||Earnings Rating||Sell|
|Market Cap||4.93B||Earnings Date||8th Aug 2022|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||8th Aug 2022|
|Estimated EPS Next Report||-1.36|
|EPS Growth Next 5 Years %||19.30|
|Avg. Weekly Volume||941.43K|
|Avg. Monthly Volume||812.05K|
|Avg. Quarterly Volume||1.08M|
Apellis Pharmaceuticals Inc. (NASDAQ: APLS) stock closed at 46.26 per share at the end of the most recent trading day (a -1.57% change compared to the prior day closing price) with a volume of 1.82M shares and market capitalization of 4.93B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 374 people. Apellis Pharmaceuticals Inc. CEO is Cedric Francois.
The one-year performance of Apellis Pharmaceuticals Inc. stock is -25.48%, while year-to-date (YTD) performance is -2.16%. APLS stock has a five-year performance of %. Its 52-week range is between 27.5 and 73, which gives APLS stock a 52-week price range ratio of 41.23%
Apellis Pharmaceuticals Inc. currently has a PE ratio of -5.60, a price-to-book (PB) ratio of 10.17, a price-to-sale (PS) ratio of 58.09, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -73.44%, a ROC of -121.89% and a ROE of -274.60%. The company’s profit margin is -89.24%, its EBITDA margin is -841.30%, and its revenue ttm is $80.94 Million , which makes it $0.76 revenue per share.
Of the last four earnings reports from Apellis Pharmaceuticals Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-1.36 for the next earnings report. Apellis Pharmaceuticals Inc.’s next earnings report date is 08th Aug 2022.
The consensus rating of Wall Street analysts for Apellis Pharmaceuticals Inc. is Strong Buy (1.46), with a target price of $70.38, which is +52.14% compared to the current price. The earnings rating for Apellis Pharmaceuticals Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Apellis Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Apellis Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 7.52, ATR14 : 2.78, CCI20 : 144.19, Chaikin Money Flow : 0.10, MACD : 0.43, Money Flow Index : 61.04, ROC : 2.50, RSI : 57.79, STOCH (14,3) : 83.66, STOCH RSI : 0.84, UO : 59.88, Williams %R : -16.34), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Apellis Pharmaceuticals Inc. in the last 12-months were: A. Sinclair Dunlop (Option Excercise at a value of $376 516), Alec Machiels (Option Excercise at a value of $57 405), Alec Machiels (Sold 21 500 shares of value $980 928 ), Cedric Francois (Option Excercise at a value of $62 107), David Watson (Option Excercise at a value of $293 786), David Watson (Sold 16 771 shares of value $813 573 ), Federico Grossi (Option Excercise at a value of $173 441), Federico Grossi (Sold 9 250 shares of value $399 253 ), Lukas Scheibler (Option Excercise at a value of $593 182), Lukas Scheibler (Sold 48 508 shares of value $2 374 439 ), Mark Jeffrey DeLong (Option Excercise at a value of $278 180), Mark Jeffrey DeLong (Sold 19 000 shares of value $912 860 ), Nicole Perry (Option Excercise at a value of $7 520), Nicole Perry (Sold 2 000 shares of value $127 990 ), Pascal Deschatelets (Option Excercise at a value of $148 198), Pascal Deschatelets (Sold 16 000 shares of value $706 800 ), Victoria L. Brown (Sold 2 698 shares of value $121 410 )
Tue, 24 May 2022 12:45 GMT Apellis Pharmaceuticals (APLS) Receives a Buy from Goldman Sachs- TipRanks. All rights reserved.
Tue, 12 Apr 2022 10:36 GMT Apellis Pharmaceuticals (APLS) Gets a Buy Rating from Needham- TipRanks. All rights reserved.
Mon, 04 Apr 2022 16:42 GMT Apellis Pharmaceuticals (APLS) Gets a Buy Rating from J.P. Morgan- TipRanks. All rights reserved.
Thu, 03 Mar 2022 10:23 GMT Apellis Pharmaceuticals (APLS) Gets a Buy Rating from Robert W. Baird- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro. Your capital is at risk.
This could take some time, please wait.